Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul-Aug;33(4):1051-1058.
doi: 10.21873/invivo.11573.

Pharmacogenetic Implications of eNOS Polymorphisms (Glu298Asp, T786C, 4b/4a) in Cardiovascular Drug Therapy

Angela Cozma #  1   2 , Adriana Fodor #  1   3 , Olga Hilda Orasan #  1   2 , Romana Vulturar  1   4 , Dorel Samplelean  1   2 , Vasile Negrean  1   2 , Crina Muresan  5 , Ramona Suharoschi  6 , Adela Sitar-Taut  1   2
Affiliations
Review

Pharmacogenetic Implications of eNOS Polymorphisms (Glu298Asp, T786C, 4b/4a) in Cardiovascular Drug Therapy

Angela Cozma et al. In Vivo. 2019 Jul-Aug.

Abstract

Endothelial nitric oxide synthase (NOS3 or eNOS) is the enzyme responsible for the highest production of nitric oxide, with the greatest impact on the cardiovascular system, encoded by the eNOS gene, which presents various polymorphisms. ENOS gene polymorphisms play an important role in the response to drugs affecting nitric oxide (NO) signaling. This review discusses the pharmacogenetic impact of eNOS polymorphisms on the response to drugs affecting NO activity: angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, calcium blockers, beta-blockers, diuretics, phosphodiesterase inhibitors, and statins. The identification of biomarkers that accurately predict particular phenotypes is a challenge that needs additional large studies, in different populations. Efforts should be oriented towards a more accurate evaluation of the effects of eNOS genetic variants on biochemical parameters reflecting eNOS gene expression and enzymatic activity, in different diseases, as well as following drug treatment. This approach will allow for a better understanding of the role of eNOS genetic variants in cardiovascular disease progression and for cardiovascular drug therapy optimization.

Keywords: Cardiovascular drug; eNOS; nitric oxide; pharmacogenetics; polymorphisms; review.

PubMed Disclaimer

Conflict of interest statement

The Authors declare that there are no conflicts of interest.

References

    1. Lacchini R, Silva PS, Tanus-Santos JE. A pharmacogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins. Basic Clin Pharmacol Toxicol. 2010;106:357–361. PMID: 20210789. DOI: 10.1111/j.1742-7843. 2010.00551.x. - PubMed
    1. Haga SB, LaPointe NM. The potential impact of pharmacogenetic testing on medication adherence. Pharm J. 2013;13:481–483. PMID 23999596. DOI: 10.1038/tpj.2013.33. - PMC - PubMed
    1. Evans WE, McLeod HL. Pharmacogenomics–drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538–549. PMID: 12571262. DOI: 10.1056/NEJMra020526. - PubMed
    1. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364:1144–1153. PMID: 21428770. DOI: 10.1056/NEJMra1010600. - PMC - PubMed
    1. Li H, Wallerath T, Münzel T, Förstermann U. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide. 2002;7(3):149–164. PMID: 12381413. - PubMed

MeSH terms

LinkOut - more resources